Literature DB >> 25840970

Global Transcriptional Changes Following Statin Treatment in Breast Cancer.

Olöf Bjarnadottir1, Siker Kimbung2, Ida Johansson2, Srinivas Veerla3, Mats Jönsson2, Pär-Ola Bendahl2, Dorthe Grabau2, Ingrid Hedenfalk2, Signe Borgquist4.   

Abstract

BACKGROUND: Statins purportedly exert antitumoral effects, but the underlying mechanisms are currently not fully elucidated. The aim of this study was to explore potential statin-induced effects on global gene expression profiles in primary breast cancer. EXPERIMENTAL
DESIGN: This window-of-opportunity phase II trial enrolled 50 newly diagnosed breast cancer patients prescribed atorvastatin (80 mg/day) for 2 weeks presurgically. Pre- and posttreatment tumor samples were analyzed using Significance Analysis of Microarrays (SAM) to identify differentially expressed genes. Similarly, SAM and gene ontology analyses were applied to gene expression data derived from atorvastatin-treated breast cancer cell lines (MCF7, BT474, SKBR3, and MDAMB231) comparing treated and untreated cells. The Systematic Motif Analysis Retrieval Tool (SMART) was used to identify enriched transcription factor-binding sites. Literature Vector Analysis (LitVAn) identified gene module functionality, and pathway analysis was performed using GeneGo Pathways Software (MetaCore; https://portal.genego.com/).
RESULTS: Comparative analysis of gene expression profiles in paired clinical samples revealed 407 significantly differentially expressed genes (FDR = 0); 32 upregulated and 375 downregulated genes. Restricted filtration (fold change ≥1.49) resulted in 21 upregulated and 46 downregulated genes. Significantly upregulated genes included DUSP1, RHOB1, GADD45B, and RGS1. Pooled results from gene ontology, LitVAn and SMART analyses identified statin-induced effects on the apoptotic and MAPK pathways among others. Comparative analyses of gene expression profiles in breast cancer cell lines showed significant upregulation of the mevalonate and proapoptotic pathways following atorvastatin treatment.
CONCLUSIONS: We report potential statin-induced changes in global tumor gene expression profiles, indicating MAPK pathway inhibition and proapoptotic events. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25840970     DOI: 10.1158/1078-0432.CCR-14-1403

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  21 in total

1.  Statin use and breast cancer survival: a nationwide cohort study in Scotland.

Authors:  Úna C Mc Menamin; Liam J Murray; Carmel M Hughes; Chris R Cardwell
Journal:  BMC Cancer       Date:  2016-08-04       Impact factor: 4.430

2.  CtBP promotes metastasis of breast cancer through repressing cholesterol and activating TGF-β signaling.

Authors:  Zhiqiang Zhao; Dapeng Hao; Li Wang; Jingjing Li; Yuan Meng; Peipei Li; Yuan Wang; Chao Zhang; Haisheng Zhou; Kevin Gardner; Li-Jun Di
Journal:  Oncogene       Date:  2018-11-15       Impact factor: 9.867

3.  De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I-III breast cancer.

Authors:  Amelia Smith; Laura Murphy; Linda Sharp; Darran O'Connor; William M Gallagher; Kathleen Bennett; Thomas I Barron
Journal:  Br J Cancer       Date:  2016-08-02       Impact factor: 7.640

4.  Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency.

Authors:  Hae Hyun Jung; Soo-Hyeon Lee; Ji-Yeon Kim; Jin Seok Ahn; Yeon Hee Park; Young-Hyuck Im
Journal:  Sci Rep       Date:  2016-09-08       Impact factor: 4.379

Review 5.  Current and Emerging Uses of Statins in Clinical Therapeutics: A Review.

Authors:  Jonathan T Davies; Spencer F Delfino; Chad E Feinberg; Meghan F Johnson; Veronica L Nappi; Joshua T Olinger; Anthony P Schwab; Hollie I Swanson
Journal:  Lipid Insights       Date:  2016-11-14

6.  Lovastatin induced Kruppel like factor 2 (KLF2), Kruppel like factor 6 (KLF6) and Ras homolog family member B (RHOB) genes and preferentially led to viability reduction of Cisplatin-resistant cells.

Authors:  Chiho Koi; Hiroto Izumi; Tomoko Kurita; Thuy Thi Nguyen; Midori Murakami; Yukiko Yoshiura; Toru Hachisuga; Yasuo Morimoto
Journal:  Oncotarget       Date:  2017-11-16

Review 7.  Marketed drugs used for the management of hypercholesterolemia as anticancer armament.

Authors:  Panagiota Papanagnou; Theodora Stivarou; Ioannis Papageorgiou; Georgios E Papadopoulos; Anastasios Pappas
Journal:  Onco Targets Ther       Date:  2017-09-08       Impact factor: 4.147

Review 8.  Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs.

Authors:  Kush K Patel; Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2021-06-12       Impact factor: 5.858

9.  Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.

Authors:  Tingting Wang; Serena Seah; Xinyi Loh; Ching-Wan Chan; Mikael Hartman; Boon-Cher Goh; Soo-Chin Lee
Journal:  Oncotarget       Date:  2016-01-19

10.  High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer.

Authors:  Siker Kimbung; Barbara Lettiero; Maria Feldt; Ana Bosch; Signe Borgquist
Journal:  Oncotarget       Date:  2016-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.